BFRIW实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (28 Jun 2024 @ 04:00):
Our systems believe the stock currently is undervalued by 0.13% compare to its pairs and should correct upwards.

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States...

Stats
今日成交量	7 410
平均成交量	0
市值	4.36M
EPS	$-2.88 ( Q1 \| 2024-05-15 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0300 (Sector) 42.63 (Industry) 30.78
ATR14	$0 (0.00%)

AERI 0.00%

ALVO 1.33%

ALVOW 6.79%

BDSI -0.09%

BFRIW -5.93%

CLVRW 0.00%

CYTHW -4.35%

ENDP 0.00%

GRVI 7.61%

HPCO 0.06%

INDV -1.59%

JUPWW -20.00%

LFCR -0.19%

LNDC -3.52%

LSDI -23.29%

PRFX -3.65%

PROCW 10.09%

QLI 6.82%

SBFMW 0.00%

SHOT 9.43%

SHPH 4.28%

Insider Trading

Date	Person	Action	Amount	type
2023-07-03	Lanckriet Heikki	Buy	0
2023-05-18	Monaco Erica L.	Buy	76 336	Common Stock
2023-05-18	Monaco Erica L.	Sell	76 336	Restricted Stock Units
2023-05-18	Luebbert Hermann	Buy	95 420	Common Stock
2023-05-18	Luebbert Hermann	Sell	95 420	Restricted Stock Units

INSIDER POWER
15.36
Last 5 transactions
Buy: 271 756 \| Sell: 171 756

相关性 (AI algo v.1.1b): Undervalued: 0.13% $0.0382 paired level. (算法实时跟踪最相关股票的变化并提供即时更新)

Biofrontera Inc. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Biofrontera Inc. 财务报表

Annual	2023
营收:	$34.07M
毛利润:	$15.56M (45.68 %)
EPS:	$-13.02

FY	2023
营收:	$34.07M
毛利润:	$15.56M (45.68 %)
EPS:	$-13.02

FY	2022
营收:	$28.67M
毛利润:	$13.49M (47.04 %)
EPS:	$-0.610

FY	2021
营收:	$24.10M
毛利润:	$11.36M (47.13 %)
EPS:	$0

Financial Reports:

No articles found.

Biofrontera Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Biofrontera Inc.

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.